AMGN vs. GILD, VRTX, REGN, ALNY, BIIB, UTHR, NBIX, INCY, BMRN, and EXEL
Should you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry.
Amgen vs.
Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, community ranking, institutional ownership and media sentiment.
83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by insiders. Comparatively, 0.7% of Amgen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Gilead Sciences presently has a consensus price target of $97.96, indicating a potential upside of 4.76%. Amgen has a consensus price target of $314.91, indicating a potential upside of 15.14%. Given Amgen's higher possible upside, analysts clearly believe Amgen is more favorable than Gilead Sciences.
Gilead Sciences pays an annual dividend of $3.08 per share and has a dividend yield of 3.3%. Amgen pays an annual dividend of $9.00 per share and has a dividend yield of 3.3%. Gilead Sciences pays out 3,422.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 115.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has raised its dividend for 14 consecutive years.
Amgen has lower revenue, but higher earnings than Gilead Sciences. Amgen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
Gilead Sciences received 922 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 76.88% of users gave Gilead Sciences an outperform vote while only 72.07% of users gave Amgen an outperform vote.
Gilead Sciences has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.
In the previous week, Amgen had 24 more articles in the media than Gilead Sciences. MarketBeat recorded 64 mentions for Amgen and 40 mentions for Gilead Sciences. Amgen's average media sentiment score of 1.20 beat Gilead Sciences' score of 1.10 indicating that Amgen is being referred to more favorably in the news media.
Amgen has a net margin of 13.00% compared to Gilead Sciences' net margin of 0.45%. Amgen's return on equity of 168.35% beat Gilead Sciences' return on equity.
Summary
Amgen beats Gilead Sciences on 13 of the 22 factors compared between the two stocks.
Get Amgen News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NASDAQ:AMGN) was last updated on 1/21/2025 by MarketBeat.com Staff
